185 related articles for article (PubMed ID: 36610489)
1. Disease profile of rheumatoid arthritis and its complications in hispanic population.
Cawley A; Bhalla S; Floresca R; Alvarado L; Dihowm F
Am J Med Sci; 2023 Apr; 365(4):337-344. PubMed ID: 36610489
[TBL] [Abstract][Full Text] [Related]
2. Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.
Reed E; Hedström AK; Hansson M; Mathsson-Alm L; Brynedal B; Saevarsdottir S; Cornillet M; Jakobsson PJ; Holmdahl R; Skriner K; Serre G; Alfredsson L; Rönnelid J; Lundberg K
Arthritis Res Ther; 2020 Jul; 22(1):170. PubMed ID: 32678001
[TBL] [Abstract][Full Text] [Related]
3. Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry.
Huang S; He X; Doyle TJ; Zaccardelli A; Marshall AA; Friedlander HM; Blaustein RB; Smith EA; Cui J; Iannaccone CK; Mahmoud TG; Weinblatt ME; Dellaripa PF; Shadick NA; Sparks JA
Clin Rheumatol; 2019 Dec; 38(12):3401-3412. PubMed ID: 31410660
[TBL] [Abstract][Full Text] [Related]
4. Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients.
Sulaiman FN; Wong KK; Ahmad WAW; Ghazali WSW
Medicine (Baltimore); 2019 Mar; 98(12):e14945. PubMed ID: 30896663
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
Agrawal S; Misra R; Aggarwal A
Clin Rheumatol; 2007 Feb; 26(2):201-4. PubMed ID: 16572283
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
Chang PY; Yang CT; Cheng CH; Yu KH
Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
[TBL] [Abstract][Full Text] [Related]
8. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status.
Bang SY; Lee KH; Cho SK; Lee HS; Lee KW; Bae SC
Arthritis Rheum; 2010 Feb; 62(2):369-77. PubMed ID: 20112396
[TBL] [Abstract][Full Text] [Related]
9. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
[TBL] [Abstract][Full Text] [Related]
10. Effects of Aging on Rheumatoid Factor and Anticyclic Citrullinated Peptide Antibody Positivity in Patients With Rheumatoid Arthritis.
Takanashi S; Takeuchi T; Kaneko Y
J Rheumatol; 2023 Mar; 50(3):330-334. PubMed ID: 36319009
[TBL] [Abstract][Full Text] [Related]
11. Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations.
Wielosz E; Majdan M; Dryglewska M; Zwolak R
Adv Clin Exp Med; 2018 Sep; 27(9):1253-1257. PubMed ID: 30024658
[TBL] [Abstract][Full Text] [Related]
12. Increased disease activity, severity and autoantibody positivity in rheumatoid arthritis patients with co-existent bronchiectasis.
Perry E; Eggleton P; De Soyza A; Hutchinson D; Kelly C
Int J Rheum Dis; 2017 Dec; 20(12):2003-2011. PubMed ID: 26200759
[TBL] [Abstract][Full Text] [Related]
13. Association of anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes with HLA-DRB1 shared epitope alleles in Egyptian rheumatoid arthritis patients.
Raslan HM; Attia HR; Hamed Ibrahim M; Mahmoud Hassan E; Salama II; Ismail S; Abdelmotaleb E; El Menyawi MM; Amr KS
Int J Rheum Dis; 2020 May; 23(5):647-653. PubMed ID: 32167241
[TBL] [Abstract][Full Text] [Related]
14. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of treatment patterns and healthcare utilization of newly-diagnosed rheumatoid arthritis patients by anti-cyclic citrullinated peptide antibody status.
Lamerato L; Price K; Szymialis R; Eaddy M; Ogbonnaya A; Shih HC; Ahmad H
J Med Econ; 2018 Mar; 21(3):231-240. PubMed ID: 29027497
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
[TBL] [Abstract][Full Text] [Related]
17. Validation of serostatus of rheumatoid arthritis using ICD-10 codes in administrative claims data.
Lee H; Sparks JA; Lee SB; Yoshida K; Landon JE; Kim SC
Pharmacoepidemiol Drug Saf; 2023 May; 32(5):586-591. PubMed ID: 36728737
[TBL] [Abstract][Full Text] [Related]
18. Double positivity for rheumatoid factor and anti-CCP autoantibodies: improving referral from primary care of patients suspected of having rheumatoid arthritis.
Salinas M; Blasco Á; Flores E; Minguez M; Leiva-Salinas C
Prim Health Care Res Dev; 2024 Jan; 25():e6. PubMed ID: 38229558
[TBL] [Abstract][Full Text] [Related]
19. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
[TBL] [Abstract][Full Text] [Related]
20. The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years.
da Mota LM; Dos Santos Neto LL; de Carvalho JF; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
Rheumatol Int; 2012 Dec; 32(12):3807-12. PubMed ID: 22187055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
